ReviewClinical and experimental medicine2026
The oncogenic role, regulatory mechanism, and clinical significance of lncRNA HIF1A-AS2 in multiple human cancers.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) are RNA molecules transcribed over 200 nucleotides in length. Although they do not encode proteins, many studies have shown that they have a dramatic involvement in human cancer by various mechanisms. Hypoxia inducible factor 1α-antisense RNA 2 (HIF1A-AS2) is a lncRNA recently described to map on human chromosome 14q23.2, whose aberrant expression has been observed in many tumor types and whose up-regulation results in poor patient clinical prognosis. Experimental studies demonstrate that HIF1A-AS2 is involved in a wide range of biological processes, including cell proliferation, invasion, migration, apoptosis, drug resistance and epithelial-mesenchymal transition (EMT). Moreover, this lncRNA promotes cancer malignancy by acting as competing endogenous RNA (ceRNA) or by directly binding to certain proteins. This article comprehensively summarizes the function, molecular mechanisms, and clinical significance of HIF1A-AS2 in malignant tumors, pointing out that HIF1A-AS2 has potential functions as diagnostic markers as well as therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.